Clinical Updates
Kentucky Law Restricts Opioid Prescribing
Kentucky is following several other states that have recently enacted new laws to restrict opioid…
DEA Proposes Reduction in Manufacturing of Opioids for 2018
The DEA has proposed to reduce the manufacturing of controlled substances in the United States…
Launch of Generic Relpax
The generic equivalent of Relpax (Eletriptan) has just been released, following FDA approval. Relpax is…
Louisiana Enacts New Laws Regarding Opioid Prescribing Limits
Louisiana joined several states in enacting new laws limiting the days’ supply of a new…
Endo Pharmaceuticals, Inc. Announces Withdrawal of Opana ER
Endo Pharmaceuticals announced it would be voluntarily withdrawing Opana ER (Oxymorphone ER) from the market….
Launch of Generic Butrans
The FDA has recently approved the generic equivalent of Butrans (Buprenorphine) transdermal patches. Butrans is…
Launch of Generic Strattera
The generic equivalent of Strattera (Atomoxetine) has just been released, following FDA approval. Strattera is…
Launch of Generic Vytorin
The generic equivalent of Vytorin (ezetimibe/simvastatin) has just been released, following FDA approval. Vytorin is…
Gabapentin to Become a Controlled Substance in Kentucky
Kentucky will become the first state to change gabapentin to a Schedule V controlled substance,…
Launch of Generic Pristiq
The generic equivalent of Pristiq (Desvenlafaxine) has just been released, following FDA approval. Pristiq is…
